STEMI

0
Pipeline Programs
4
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Rhythm Pharmaceuticals
2 programs
The coronary sinus balloon pumpN/A1 trial
the coronary sinus balloon pumpN/A1 trial
Active Trials
NCT07354035Not Yet Recruiting177Est. Jun 2026
NCT07082153Not Yet Recruiting10Est. Mar 2026
T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
Dosing Oxidative stress biomarkers & hFABP in STEMI pPCI patientsN/A1 trial
Active Trials
NCT04034940UnknownEst. Aug 2020
Miracor Medical
Miracor MedicalBelgium - Awans
1 program
PiCSON/A1 trial
Active Trials
NCT03625869CompletedEst. Feb 2023
Zoll
ZollCA - San Jose
1 program
SSO2 therapyN/A1 trial
Active Trials
NCT05790876CompletedEst. Jun 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Rhythm PharmaceuticalsThe coronary sinus balloon pump
Rhythm Pharmaceuticalsthe coronary sinus balloon pump
ZollSSO2 therapy
T-TherapeuticsDosing Oxidative stress biomarkers & hFABP in STEMI pPCI patients
Miracor MedicalPiCSO

Clinical Trials (5)

Total enrollment: 187 patients across 5 trials

NCT07354035Rhythm PharmaceuticalsThe coronary sinus balloon pump

The Coronary Sinus Balloon Pump in STEMI

Start: Feb 2026Est. completion: Jun 2026177 patients
N/ANot Yet Recruiting
NCT07082153Rhythm Pharmaceuticalsthe coronary sinus balloon pump

The First-In-Man Use of Coronary Sinus Balloon Pump in STEMI Patients Treated by Primary PCI

Start: Aug 2025Est. completion: Mar 202610 patients
N/ANot Yet Recruiting
NCT05790876ZollSSO2 therapy

Super Saturated Oxygen (SSO2) Therapy in Patients With ST-segment Elevation Myocardial Infarction (STEMI) and Action on Coronary Microcirculation Dysfunction

Start: Mar 2023Est. completion: Jun 2025
N/ACompleted
NCT04034940T-TherapeuticsDosing Oxidative stress biomarkers & hFABP in STEMI pPCI patients

Correlations Between Oxidative Stress Biomarkers, h-FABP and Left Ventricular Dysfunction in Patients With Acute Myocardial Infarction Undergoing Primary PCI

Start: Aug 2019Est. completion: Aug 2020
N/AUnknown

Pressure-controlled Intermittent Coronary Sinus Occlusion (PiCSO) in Acute Myocardial Infarction

Start: Jul 2019Est. completion: Feb 2023
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space